“In our first studies of TCAP in rodents, I was struck by the low toxicity profile of the peptide. The animals remained calm and healthy even after TCAP doses of over ten times the effective dose. I knew then that we had something important. ” – Dalia Barsyte, PhD
Dr. Barsyte received her Ph.D. in molecular and cellular biology from the University of Manchester, UK. Her postdoctoral training at the University of Manchester and Ontario Cancer Institute, Canada focused on characterizing cellular signaling mechanisms. Dr. Barsyte is an inventor on one of the key Protagenic Therapeutics patents and author of over 50 scientific publications in oncology and neuroscience. Dr. Barsyte’s scientific interests include exploring chemical biology in therapeutic target validation through peptide or small molecule chemical probe compounds as well as novel in vitro models of disease based on patient derived cell culture.
© 2022 Protagenic Therapeutics, Inc.
Built by Techtegic
